Dr Lal PathLabs to acquire 70 pc stake in SN Genelab for Rs 168 crore

Dr Lal PathLabs Ltd is set to acquire a 70% stake in SN Genelab for around Rs 168 crore, expanding its capabilities in genomics and diagnostic services. This move includes a potential earn-out of Rs 31.5 crore tied to performance. With the deal expected to close by November 30, 2026, SN Genelab will transition into a subsidiary of Dr Lal PathLabs.